Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Evelo Biosciences Inc (EVLO)

Evelo Biosciences Inc (EVLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9
  • Shares Outstanding, K 18,983
  • Annual Sales, $ 0 K
  • Annual Income, $ -114,530 K
  • EBIT $ -77 M
  • EBITDA $ -75 M
  • 60-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -13.01
  • Most Recent Earnings N/A on 11/09/23
  • Next Earnings Date 12/26/24 [--]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0003 +66.67%
on 12/13/24
0.0015 -66.67%
on 11/22/24
-0.0010 (-66.67%)
since 11/19/24
3-Month
0.0001 +400.00%
on 10/11/24
0.0015 -66.67%
on 11/22/24
+0.0004 (+400.00%)
since 09/18/24
52-Week
0.0001 +400.00%
on 10/11/24
0.1000 -99.50%
on 12/21/23
-0.0435 (-98.86%)
since 12/19/23

Most Recent Stories

More News
Stocks Move Higher Before the Open as Focus Shifts to Fed Meeting Next Week

September S&P 500 futures (ESU23) are up +0.25%, and September Nasdaq 100 E-Mini futures (NQU23) are up +0.36% this morning after three major U.S. benchmark indices closed mixed on Thursday as market participants...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
JNJ : 144.47 (+0.62%)
NFLX : 909.05 (+0.78%)
TSLA : 421.06 (-3.46%)
AMAT : 163.59 (+1.33%)
AMD : 119.21 (+0.28%)
AXP : 298.65 (+1.90%)
SLB : 36.83 (-0.22%)
ROP : 525.40 (+0.70%)
SAP.D.DX : 237.900 (+0.08%)
LONN.Z.IX : 530.200 (+0.65%)
Cellarity Strengthens Executive Leadership Team

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer...

IMPL : 0.0400 (-27.27%)
SELB : 0.8812 (-8.00%)
MDGN : 5.57 (+3.15%)
DNLI : 21.45 (-0.19%)
EVLO : 0.0005 (unch)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Flagship Pioneering Unveils Ampersand Biomedicines to Create Highly Effective Medicines That Are Programed to Act Only Where Needed

Flagship Pioneering, the bioplatform innovation company, today unveiled Ampersand Biomedicines, a company creating programmable medicines that are safer, more tolerable, and effective by acting at the...

DNLI : 21.45 (-0.19%)
EVLO : 0.0005 (unch)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a multi-program agreement with Pioneering Medicines, a strategic initiative of Flagship Pioneering, that gives Pioneering Medicines...

CRL : 185.77 (+1.99%)
DNLI : 21.45 (-0.19%)
EVLO : 0.0005 (unch)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Horizon Technology Finance Provides Fourth Quarter 2022 Portfolio Update

/PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in...

HRZN : 8.85 (+0.23%)
EVLO : 0.0005 (unch)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Evelo Biosciences, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

/PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of...

EVLO : 0.0005 (unch)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 21.45 (-0.19%)
EVLO : 0.0005 (unch)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
RUBY : 0.0570 (+2.70%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 21.45 (-0.19%)
EVLO : 0.0005 (unch)
FHTX : 5.14 (+3.21%)
MRNA : 39.39 (-0.43%)
OMGA : 0.8369 (+3.02%)
RUBY : 0.0570 (+2.70%)
SANA : 1.6500 (+3.12%)
MCRB : 0.9155 (-0.59%)
Evelo Biosciences, Inc. (EVLO) Q2 2022 Earnings Call Transcript

EVLO earnings call for the period ending June 30, 2022.

EVLO : 0.0005 (unch)
Evelo Biosciences Announces Succession Plan

– Simba Gill to transition to Chair of the Board of Directors –– Lord Ara Darzi will become Lead Independent Director –– Board has retained Spencer Stuart...

EVLO : 0.0005 (unch)

Business Summary

Evelo Biosciences, Inc. operates as a bio-technology company. It develops therapies for the treatment of the gut-body network. The company also offers treatment for cancer and inflammatory diseases. Its product portfolio consists of EDP1066 which are in clinical stage. Evelo Biosciences is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 0.0005
2nd Resistance Point 0.0005
1st Resistance Point 0.0005
Last Price 0.0005
1st Support Level 0.0005
2nd Support Level 0.0005
3rd Support Level 0.0005

See More

52-Week High 0.1000
Fibonacci 61.8% 0.0618
Fibonacci 50% 0.0501
Fibonacci 38.2% 0.0383
Last Price 0.0005
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar